Replies to post #203911 on Avid Bioservices Inc (CDMO)

[biopharm]

Harold Dvorak : Peregrine Pharmaceuticals KOL : Cancer starts with Inflammation : Part II

...chronic inflammation fuels cancer.

ok, so you have all heard this year the common theme that immuno-oncology is the next big thing, the next big wave. Well... I would say its not just the next big wave but more like any wave no one has ever seen before, especially Big Pharma when it wipes some of them off the map and out of business and who will be left standing is the question.

Increase in certain MDSC's leads to (along with down to protein level blood based biomarkers...etc ) inflammation which leads to chronic inflammation which yes, all leads to a tumor big enough that we can what we call today cancer. The paradigm shift also includes knowing and understanding the protein level changes that initially take place, in order to force a sea of change = Immuno-Oncology.

Lets start with Dr. Rolf Brekken:

Dr. Rolf Brekken received his Bachelor of Arts degree from Luther College in Decorah, Iowa and his PhD from UT Southwestern Graduate School of Biomedical Sciences. His graduate research was focused in the use of Vascular Endothelial Growth Factor (VEGF) as a target for the therapy of solid tumors. He completed his postdoctoral training in the Department of Vascular Biology at the Hope Heart Institute in Seattle, Washington.

http://profiles.utsouthwestern.edu/profile/10808/rolf-brekken.html

http://en.wikipedia.org/wiki/Vascular_endothelial_growth_factor

----------------------------------------------------------

Remember the days when PS Targeting was thought to simple target the blood supply and acting like VEGF-targeted therapies = with the notion that they would inhibit new blood vessel growth and thus starve tumours of necessary oxygen and nutrients, and that was the reason for its success? Well don't feel bad, many Big Pharma drugs were FDA approved on similar paths and possibly would be overturned with the knowledge of how those drugs were working re: against the immune system and what was happening exactly at the protein level.

So how about this question:

Why Doesn’t Anti-VEGF Therapy Work Better in Cancer?

Well... maybe Peregrine KOL Harolf Dvorak will be asked a very simple question tomorrow in regards to Bavituximab and the MOA and why it works. He certainly knows about Bavituximab and the MOA and if asked the question he certainly can not say he has never heard of PS Targeting like some Bristol Myers Squibb players... right?

-------------------------------------------

When Thursday, May 21, 2015, 4:30 – 5:30pm
Where Folkman Auditorium, Enders Bldg.
Boston Children's Hospital
300 Longwood Ave.
Topics Vascular Biology
Event Types Seminar Series
Location Children's Hospital Boston
RSVP Required No

Note

Seventh Annual Judah Folkman, MD Lecture
Harold F. Dvorak, MD
Mallinckrodt Distinguished Professor of Pathology
Harvard Medical School
Center for Vascular Biology Research
Center for Cancer Research
Beth Israel Deaconess Medical Center
Boston, MA

"Why Doesn’t Anti-VEGF Therapy Work Better in Cancer?"

http://hms.harvard.edu/calendar#/?i=1

Wouldn't it be something if Rolf Brekken and Harolf Dvorak were allowed to reveal a little something more tomorrow ? My bet would be on Rolf Brekken being asked a couple direct questions tomorrow. This paradigm shift will only become more and more interesting and apparent when the blood biomarkers that "Foundation Medicine" is working on with all the data.

Lets go Harold... surprise us some...soon.